Order Article Reprints

Wußmann M, Groeber-Becker FK, Riedl S, Alihodzic D, Padaric D, Gerlitz L, Stallinger A, Liegl-Atzwanger B, Zweytick D, Rinner B. In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis. Biomedicines. 2022; 10(11):2961. https://doi.org/10.3390/biomedicines10112961

Wußmann, Maximiliane, Florian Kai Groeber-Becker, Sabrina Riedl, Dina Alihodzic, Daniel Padaric, Lisa Gerlitz, Alexander Stallinger, Bernadette Liegl-Atzwanger, Dagmar Zweytick, and Beate Rinner. 2022. "In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis" Biomedicines 10, no. 11: 2961. https://doi.org/10.3390/biomedicines10112961

Wußmann, M., Groeber-Becker, F. K., Riedl, S., Alihodzic, D., Padaric, D., Gerlitz, L., Stallinger, A., Liegl-Atzwanger, B., Zweytick, D., & Rinner, B. (2022). In Model, In Vitro and In Vivo Killing Efficacy of Antitumor Peptide RDP22 on MUG-Mel2, a Patient Derived Cell Line of an Aggressive Melanoma Metastasis. Biomedicines, 10(11), 2961. https://doi.org/10.3390/biomedicines10112961